• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

    1.110 -0.010 (-0.89%)
    Streaming Delayed Price Updated: 11:25 AM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Sunshine Biopharma Inc. - Common stock

    < Previous 1 2 3 Next >
    News headline image
    Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
    From Sunshine Biopharma Inc.
    Via ACCESS Newswire
    News headline image
    A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
    EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
    A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
    From MarketNewsUpdates.com
    Via GlobeNewswire
    News headline image
    Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
    From Sunshine Biopharma Inc.
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
    From Sunshine Biopharma Inc.
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
    From Sunshine Biopharma Inc.
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
    From Sunshine Biopharma Inc.
    Via ACCESS Newswire
    News headline image
    Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
    From Sunshine Biopharma Inc.
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
    From Sunshine Biopharma Inc.
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
    From Sunshine Biopharma Inc.
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
    Via ACCESS Newswire
    News headline image
    Stocks to Watch: NDRA, SBFM, GOVX, HIVE, ANY Trading Actively NOW!
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Beats Q1 Expectations, TAEUS® Liver Imaging Advances and Strategic Review Acceleration Fuels Investor Awareness
    Via AB Newswire
    News headline image
    Stocks Under $1: NXXT, TOON, VRAX, AIM, SBFM on Breakout Watch
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
    Via ACCESS Newswire
    BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Closes $6 Million Public Offering
    Via Investor Brand Network
    News headline image
    Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Stock is 34% Higher Since September as Investors Reward Performance Combined with Innovation (NASDAQ: SBFM)
    Via AB Newswire
    News headline image
    Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
    Via ACCESS Newswire
    News headline image
    Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections
    Via ACCESS Newswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.